Health-service use in women with binge eating disorders

About this resource

Objective: To compare health-care utilization between participants who met DSM-IV criteria for binge eating disorder (BED) and those engaged in recurrent binge eating (RBE) and to evaluate whether objective binge eating (OBE) days, a key measurement for diagnosing BED, predicted health-care costs. Method: We obtained utilization and cost data from electronic medical records to augment patient reported data for 100 adult female members of a large health maintenance organization who were enrolled in a randomized clinical trial to treat binge eating. Results: Total costs did not differ between the BED and RBE groups ($\beta$ = ˆ’0.117, z = ˆ’0.48, p = .629), nor did the number of OBE days predict total costs ($\beta$ = ˆ’0.017, z = ˆ’1.01, p = .313). Discussion: Findings suggest that the medical impairment, as assessed through health care costs, caused by BED may not be greater than impairment caused by RBE. The current threshold number of two OBE days/week as a criterion for BED may need to be reconsidered. (c) 2010 by Wiley Periodicals, Inc. Int J Eat Disord 2011

AuthorDickerson, John F.; Debar, Lynn; Perrin, Nancy a.; Lynch, Frances; Wilson, G. Terence; Rosselli, Francine; Kraemer, Helena C. & Striegel-Moore, Ruth H.
JournalInternational Journal of Eating Disorders
Volume44(6):524-530
Year2011

See also

Bulimia nervosa-nonpurging subtype: Closer to the bulimia nervosa-purging subtype or to binge eating disorder?

Objective DSM-5 has dropped subtyping of bulimia nervosa (BN), opting to continue inclusion of the somewhat contentious diagnosis of BN-nonpurging subtype (BN-NP) within a broad BN category.

Read more

The prevalence and correlates of eating disorders in the national comorbidity survey replication

Background: Little population-based data exist on the prevalence or correlates of eating disorders.

Read more

Predictors and mediators of treatment outcome in patients with binge eating disorder

A randomized controlled trial (N=52) was conducted comparing cognitive-behavioral therapy with a waiting list control group to identify mediators and predictors of treatment outcome.

Read more

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial

BACKGROUND: Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes.

Read more

Help us improve!

Give us feedback!

We will continue throughout 2020 to update and improve the NEDC website and welcome any feedback you may have on the site.

Provide feedback